Filtered By:
Management: Marketing
This page shows you your search results in order of relevance. This is page number 20.
Order by Relevance | Date
Total 30894 results found since Jan 2013.
Cadmium and lead in geophagic clay consumed in Southern Nigeria: health risk from such traditional nutraceutical
This study investigated the level of toxic metals (Cd and Pb) in 20 Nigerian geophagic clays intended for both local consumption and distribution to the West Africa market. After sampling in 4 open markets in southern Nigeria (Akwa Ibom, Abia, Rivers, Imo), samples were subjected to digestion, ashing and analysis. The Pb levels in all samples exceeded the WHO/FAO maximum permissible limit of 0.1 mg kg−1 whereas 16% exceeded the Cd limit of 0.3 mg kg−1. The estimated daily intake of Pb for all samples ranged from 0.0032 –0.0286 mg kgbw−1 day−1 to 0.0024 –0.0215 mg kgbw−1 day−1 for children and adul...
Source: Environmental Geochemistry and Health - June 29, 2020 Category: Environmental Health Source Type: research
New Phase 3 Data Show First-in-Class TREMFYA ® (guselkumab) Achieved Complete Skin Clearance and Favorable Joint Efficacy in Adult Patients with Active Psoriatic Arthritis (PsA) Through Two Years
SPRING HOUSE, PENNSYLVANIA, March 16, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term data from the Phase 3 DISCOVER-2a study showing that the skin clearance, joint symptom relief, and safety of TREMFYA® (guselkumab) previously demonstrated through 24 weeks and one year (Week 52) in adults with active psoriatic arthritis (PsA) continued through two years (Week 112).1,2 These findings also confirmed that the robust efficacy TREMFYA demonstrated in patients at Week 24 on physical function, physical aspects of health-related quality of life, and resolution of enthesitisb and d...
Source: Johnson and Johnson - March 16, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Phase 3 Data Showed First-in-Class TREMFYA ® (guselkumab) Provided Durable Complete Skin Clearance Through Five Years in Moderate to Severe Plaque Psoriasis (PsO) and Robust Joint Symptom Improvement Through 52 Weeks in Active Psoriatic Arthritis (PsA)
SPRING HOUSE, PENNSYLVANIA, April 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new Phase 3 data which showed TREMFYA® (guselkumab) sustained durable, complete skin clearance rates in a majority of adults with moderate to severe plaque psoriasis (PsO) through five years (252 weeks), a and improved disease activity and axial symptoms in adults with active psoriatic arthritis (PsA) through one year (52 weeks).1,2,3 These data are being presented at the American Academy of Dermatology Virtual Meeting Experience 2021, where Janssen will present a total of 22 abstracts. TREMFYA is t...
Source: Johnson and Johnson - April 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
IJERPH, Vol. 18, Pages 8324: An Assessment of Government Capacity Building to Restrict the Marketing of Unhealthy Food and Non-Alcoholic Beverage Products to Children in the Region of the Americas
ica I. Kraak
The Pan American Health Organization (PAHO) Strategic Plan 2020–2025 committed to reduce children’s consumption of energy-dense nutrient-poor food and beverage products high in fat, sugar and salt (HFSS) and promote healthy eating patterns to reduce malnutrition in all forms. This paper describes the capacity-building needs in PAHO’s Member States to restrict the marketing of HFSS food and beverages to children. We asked Ministries of Health officials or national institutes/departmental representatives (n = 35) to complete a 28-item web-based survey (January to July 2020). Capacity-building needs wer...
Source: International Journal of Environmental Research and Public Health - August 6, 2021 Category: Environmental Health Authors: Sof ía Rincón-Gallardo Patiño Fabio Da Silva Gomes Steven Constantinou Robin Lemaire Valisa E. Hedrick Elena L. Serrano Vivica I. Kraak Tags: Article Source Type: research
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Latest Phase 3 Data for First-in-Class TREMFYA ® (guselkumab) Demonstrates Significant and Durable Improvement in Signs and Symptoms of Active Psoriatic Arthritis while Maintaining its Safety Profile in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)
SPRING HOUSE, PENNSYLVANIA, December 3, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new TREMFYA® (guselkumab) efficacy and safety data from the Phase 3b COSMOS trial published in Annals of the Rheumatic Diseases (ARD), evaluating this selective interleukin (IL)-23 inhibitor in adults with active psoriatic arthritis (PsA) who demonstrated inadequate efficacy or intolerance to tumor necrosis factor inhibition (TNFi).1 Results showed significantly higher proportions of patients treated with TREMFYA had improvement in joint signs and symptoms and complete skin clearance versus placeb...
Source: Johnson and Johnson - December 3, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Data Show TREMFYA ® (guselkumab) Binds to Both Inflammatory Cells and Interleukin (IL)-23, Supporting a Hypothesis for a Differentiated Mechanism from Risankizumab
SPRING HOUSE, PENNSYLVANIA, May 18, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the first results of the in vitro MODIF-Y studies, supporting a hypothesis that may differentiate the mechanism of first-in-class TREMFYA® (guselkumab) from risankizumab due to the ability of TREMFYA to bind to CD64 positive (CD64+) cells in addition to interleukin (IL)-23 — both of which are key components of the immune system. 1,2 These findings, which are being presented at the Society for Investigative Dermatology (SID) annual meeting May 18-21, 2022 in Portland, Oregon, demonstrate TREMFYA bind...
Source: Johnson and Johnson - May 18, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
New Data Show Patients Treated with First-in-Class TREMFYA ® (guselkumab) Achieve Durable Efficacy Across Joint and Axial Symptoms of Active Psoriatic Arthritis Through Two Years
SPRING HOUSE, PENNSYLVANIA, June 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from Phase 3 studies demonstrating patients treated with TREMFYA® (guselkumab) achieved consistent, long-term efficacy through two years across the domains of active psoriatic arthritis (PsA) – including joint, skin, enthesitis,a dactylitis,b spinal pain and disease severityc endpoints – irrespective of baseline characteristics.1 Further analyses showed TREMFYA also provided patients with sustained improvements in measures of health-related quality of life (HRQoL), including fatigue, pain...
Source: Johnson and Johnson - June 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
IJERPH, Vol. 19, Pages 10911: Promotion of Food and Beverages by German-Speaking Influencers Popular with Adolescents on TikTok, YouTube and Instagram
This study’s objective was to assess the prevalence (exposure) and context (power) of the F&B cues in influencer content across three platforms: TikTok, YouTube, and Instagram. The selected influencers were popular with adolescents, with a combined total of more than 34 million followers/subscribers. We employed the YouTube Influencer Marketing Protocol from the World Health Organization (WHO) as our basis for coding. We analysed a total of 360 videos/posts and, of these, 24% contained F&B cues, which is equivalent to 18.1 F&B cues/hour. In total, 77% of the cues were not p...
Source: International Journal of Environmental Research and Public Health - September 1, 2022 Category: Environmental Health Authors: Eva Winzer Brigitte Naderer Simeon Klein Leah Lercher Maria Wakolbinger Tags: Article Source Type: research
New TREMFYA ® (guselkumab) Post-Hoc Analysis Reveals Early Efficacy Predicted Longer-Term Efficacy And Sustained Achievement Among A Diverse Active Psoriatic Arthritis Patient Population
SPRING HOUSE, PENNSYLVANIA, November 11, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new post-hoc analysis of the Phase 3 DISCOVER program (DISCOVER-1 and DISCOVER-2) evaluating TREMFYA® (guselkumab) in adult patients with active psoriatic arthritis (PsA), which showed that early skin and enthesitis responsesa,b predicted longer-term clinical response,c including disease remission, at week 52.1 TREMFYA is the first fully human selective interleukin (IL)-23 inhibitor therapy approved in the U.S. for adults with moderate to severe plaque psoriasis (PsO) and adults with active PsA...
Source: Johnson and Johnson - November 11, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
A Qualitative Study of Consumer‐Generated Videos about Daily Deal Web sites
This study was performed to learn more about consumers’ attitude toward deal of the day, and their motivations for purchasing (or not purchasing) daily deals. A systematic qualitative methodology called BASIC IDS was used to analyze 30 consumer‐generated YouTube videos about deal Web sites. The analysis showed that many deal‐prone consumers can be considered “deal mavens”; they take effort to learn about different sites and offerings and are eager to share their knowledge with others. Although many of these mavens show hedonistic shopping tendencies, others appear to focus mainly on utility, that is, monetary sav...
Source: Psychology and Marketing - September 12, 2013 Category: Psychiatry & Psychology Authors: Edward Boon Tags: Research Article Source Type: research
Rjukan sun: the Norwegian town that does it with mirrors
Last week for the first time ever, the winter sun shone on the Norwegian town of Rjukan. Jon Henley meets the inhabitants whose lives have been transformed – and the man who brought them sunshineOn the market square in Rjukan stands a statue of the town's founder, a noted Norwegian engineer and industrialist called Sam Eyde, sporting a particularly fine moustache. One hand thrust in trouser pocket, the other grasping a tightly rolled drawing, the great man stares northwards across the square at an almost sheer mountainside in front of him.Behind him, to the south, rises the equally sheer 1,800-metre peak known as Gaustat...
Source: Guardian Unlimited Science - November 6, 2013 Category: Science Authors: Jon Henley Tags: The Guardian The sun Culture World news Art and design Europe Features Norway Science Source Type: news
How Is Psychology Used to Manipulate and Influence Us in Our Daily Lives?
How is psychology used to manipulate and influence people in their daily lives?: originally appeared on Quora: The best answer to any question. Ask a question, get a great answer. Learn from experts and access insider knowledge. You can follow Quora on Twitter, Facebook, and Google+. Answer by Neil Eisenberg, Graduated Psychology Degree UCLA Marketing supplies a product or service that resolves the customer's problem/dilemma whether real, imagined or generated by the advertiser. If you consider this with regards to the points below, you may never watch another commercial without feeling deceived, misled and abused. 1. Hum...
Source: Science - The Huffington Post - June 25, 2015 Category: Science Source Type: news
